CN1863798B - 2,4-二氧代-3-喹唑啉基芳基磺酰基脲 - Google Patents

2,4-二氧代-3-喹唑啉基芳基磺酰基脲 Download PDF

Info

Publication number
CN1863798B
CN1863798B CN2004800287913A CN200480028791A CN1863798B CN 1863798 B CN1863798 B CN 1863798B CN 2004800287913 A CN2004800287913 A CN 2004800287913A CN 200480028791 A CN200480028791 A CN 200480028791A CN 1863798 B CN1863798 B CN 1863798B
Authority
CN
China
Prior art keywords
compound
alkyl
halogen
alkoxy
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2004800287913A
Other languages
English (en)
Chinese (zh)
Other versions
CN1863798A (zh
Inventor
罗伯特·M·斯卡伯勒
黄沃林
安贾莉·潘迪
肖恩·M·鲍尔
张晓明
照中·J·贾
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Portola Pharmaceuticals LLC
Original Assignee
Portola Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharmaceuticals LLC filed Critical Portola Pharmaceuticals LLC
Publication of CN1863798A publication Critical patent/CN1863798A/zh
Application granted granted Critical
Publication of CN1863798B publication Critical patent/CN1863798B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Hydrogenated Pyridines (AREA)
CN2004800287913A 2003-10-03 2004-09-29 2,4-二氧代-3-喹唑啉基芳基磺酰基脲 Expired - Fee Related CN1863798B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50856403P 2003-10-03 2003-10-03
US60/508,564 2003-10-03
PCT/US2004/032921 WO2005032488A2 (en) 2003-10-03 2004-09-29 2,4-dioxo-3-quinazolinylaryl sulfonylureas

Publications (2)

Publication Number Publication Date
CN1863798A CN1863798A (zh) 2006-11-15
CN1863798B true CN1863798B (zh) 2011-08-31

Family

ID=34421757

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2004800287913A Expired - Fee Related CN1863798B (zh) 2003-10-03 2004-09-29 2,4-二氧代-3-喹唑啉基芳基磺酰基脲

Country Status (15)

Country Link
US (1) US7109332B2 (https=)
EP (1) EP1668002B1 (https=)
JP (1) JP2007507551A (https=)
KR (1) KR20060113700A (https=)
CN (1) CN1863798B (https=)
AT (1) ATE448222T1 (https=)
AU (1) AU2004278030C1 (https=)
CA (1) CA2540214A1 (https=)
DE (1) DE602004024093D1 (https=)
ES (1) ES2334795T3 (https=)
IL (1) IL174446A (https=)
MX (1) MXPA06003618A (https=)
PL (1) PL1668002T3 (https=)
PT (1) PT1668002E (https=)
WO (1) WO2005032488A2 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7345049B2 (en) * 2003-12-22 2008-03-18 Ajinomoto Co., Inc. Phenylalanine derivatives
EP1812429A4 (en) * 2004-09-29 2010-07-21 Portola Pharm Inc SUBSTITUTED 2H-1,3-BENZOXAZIN-4 (3H) -ONE
PT1951254E (pt) * 2005-11-03 2012-04-12 Portola Pharm Inc [4-(6-halo-7-substituído-2,4-dioxo-1,4-di-hidro-2hquinazolin- 3-il)-fenil]-5-cloro-tiofen-2-il-sulfonilureias e formas e métodos relacionados com as mesmas
US7834023B2 (en) * 2006-09-20 2010-11-16 Portola Pharmaceuticals, Inc. Substituted dihydroquinazolines as platelet ADP receptor inhibitors
WO2008124532A1 (en) * 2007-04-05 2008-10-16 Cv Therapeutics, Inc. Quinazolinone derivatives as aldh-2 inhibitors
US20100113391A1 (en) 2007-04-19 2010-05-06 Astellas Pharma Inc. Bicyclic heterocyclic compound
WO2008137809A2 (en) * 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof
CN101654441B (zh) * 2008-08-19 2012-10-03 信谊药厂 抗凝化合物、组合物及其用途
WO2010083442A1 (en) * 2009-01-19 2010-07-22 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CA2747835A1 (en) 2009-01-19 2010-07-22 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
JP6014155B2 (ja) 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
US9630929B2 (en) 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
SG11201408284VA (en) * 2012-05-22 2015-02-27 Xenon Pharmaceuticals Inc N-substituted benzamides and their use in the treatment of pain
US10071957B2 (en) 2012-07-06 2018-09-11 Genentech, Inc. N-substituted benzamides and methods of use thereof
US9550775B2 (en) 2013-03-14 2017-01-24 Genentech, Inc. Substituted triazolopyridines and methods of use thereof
MX2015010775A (es) 2013-03-15 2016-04-25 Genentech Inc Benzoxazoles sustituidos y metodos para usarlos.
CR20160296A (es) 2013-11-27 2016-09-20 Genentech Inc Benzamidas sustituidas y métodos para usarlas
CN106715418A (zh) 2014-07-07 2017-05-24 基因泰克公司 治疗化合物及其使用方法
KR102727059B1 (ko) 2015-02-16 2024-11-05 더 유니버서티 어브 퀸슬랜드 설포닐우레아와 관련 화합물 및 그 용도
JP2018520107A (ja) 2015-05-22 2018-07-26 ジェネンテック， インコーポレイテッド 置換ベンズアミド及びその使用方法
EP3341353A1 (en) 2015-08-27 2018-07-04 Genentech, Inc. Therapeutic compounds and methods of use thereof
CN108290881B (zh) 2015-09-28 2021-12-07 健泰科生物技术公司 治疗性化合物和其使用方法
US10899732B2 (en) 2015-11-25 2021-01-26 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
EP3854782A1 (en) 2016-03-30 2021-07-28 Genentech, Inc. Substituted benzamides and methods of use thereof
AU2017347549A1 (en) 2016-10-17 2019-05-02 Genentech, Inc. Therapeutic compounds and methods of use thereof
JP2020511511A (ja) 2017-03-24 2020-04-16 ジェネンテック， インコーポレイテッド ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体
US11465992B2 (en) 2017-07-07 2022-10-11 Inflazome Limited Sulfonamide carboxamide compounds
US11542255B2 (en) 2017-08-15 2023-01-03 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
US12221434B2 (en) 2017-11-09 2025-02-11 Inflazome Limited Sulfonamide carboxamide compounds
KR20200087759A (ko) 2017-11-09 2020-07-21 인플라좀 리미티드 신규한 설폰아마이드 카복스아마이드 화합물
AR114263A1 (es) 2018-02-26 2020-08-12 Genentech Inc Compuestos terapéuticos y métodos para utilizarlos
EP3759077A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
WO2019191702A1 (en) 2018-03-30 2019-10-03 F. Hoffmann-La Roche Ag Substituted hydro-pyrido-azines as sodium channel inhibitors
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
AU2019395201A1 (en) 2018-12-06 2021-05-20 Daiichi Sankyo Company, Limited Cycloalkane-1,3-diamine derivative

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057037A1 (en) * 2000-02-04 2001-08-09 Cor Therapeutics, Inc. Platelet adp receptor inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702774D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
CA2318199A1 (en) 1998-01-15 1999-07-22 Cor Therapeutics, Inc. Platelet adp receptor inhibitors
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057037A1 (en) * 2000-02-04 2001-08-09 Cor Therapeutics, Inc. Platelet adp receptor inhibitors

Also Published As

Publication number Publication date
AU2004278030C1 (en) 2010-12-02
EP1668002A2 (en) 2006-06-14
MXPA06003618A (es) 2006-08-11
EP1668002B1 (en) 2009-11-11
IL174446A (en) 2012-02-29
CN1863798A (zh) 2006-11-15
IL174446A0 (en) 2006-08-01
US7109332B2 (en) 2006-09-19
DE602004024093D1 (de) 2009-12-24
AU2004278030A1 (en) 2005-04-14
JP2007507551A (ja) 2007-03-29
ATE448222T1 (de) 2009-11-15
ES2334795T3 (es) 2010-03-16
US20050107357A1 (en) 2005-05-19
CA2540214A1 (en) 2005-04-14
PT1668002E (pt) 2009-11-25
EP1668002A4 (en) 2006-12-20
HK1093973A1 (en) 2007-03-16
WO2005032488A3 (en) 2005-05-12
WO2005032488A2 (en) 2005-04-14
AU2004278030B2 (en) 2010-07-01
KR20060113700A (ko) 2006-11-02
PL1668002T3 (pl) 2010-02-26

Similar Documents

Publication Publication Date Title
CN1863798B (zh) 2,4-二氧代-3-喹唑啉基芳基磺酰基脲
AU2005292314B2 (en) Substituted 2H-1,3-benzoxazin-4(3H)-ones
AU2004279809B2 (en) Substituted isoquinolinones
JPWO2006057270A1 (ja) 含窒素３環化合物
EP2094272B1 (en) Nitrogen containing substituted heterocycles as platelet adp receptor inhibitors
HK1093973B (en) 2,4-dioxo-3-quinazolinylaryl sulfonylureas
CN101534832A (zh) 作为血小板adp受体抑制剂的被取代的含氮杂环类化合物
HK1111414B (en) Substituted 2h-1,3-benzoxazin-4(3h)-ones
HK1131058B (en) Nitrogen containing substituted heterocycles as platelet adp receptor inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110831

Termination date: 20120929